NCT03907475 2026-03-18
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
441 trialsNCT04443088 2026-03-18
KEYNOTE-E12
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1 Recruiting
NCT05327010 2026-03-18
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05687110 2026-03-18
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05687136 2026-03-18
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05691517 2026-03-18
Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05719558 2026-03-18
A Study of ASP1002 in Adults for Treatment of Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT06606990 2026-03-18
Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06658405 2026-03-18
HPV2
Centre Oscar Lambret
Phase 2 Recruiting
NCT07202507 2026-03-18
SNOOZE
Centre Oscar Lambret
Phase NA Recruiting
NCT04585958 2026-03-17
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05638295 2026-03-17
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05694715 2026-03-17
Combination Therapy in Cancers With Mutations in DNA Repair Genes
University of California, San Francisco
Phase 1 Recruiting
NCT04802759 2026-03-16
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05887882 2026-03-16
PNOC028
University of California, San Francisco
Phase 1 Recruiting
NCT06150157 2026-03-16
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06997029 2026-03-16
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Recruiting
NCT07030712 2026-03-16
MK-8294-001
Merck Sharp & Dohme LLC
Phase 1 Recruiting
NCT05862285 2026-03-13
UmbrellaMAX
Hoffmann-La Roche
Phase 3 Recruiting
NCT05909202 2026-03-13
A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
National Institutes of Health Clinical Center (CC)
Phase NA Recruiting
NCT06178614 2026-03-13
A Study of JNJ-87890387 for Advanced Solid Tumors
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06941272 2026-03-13
MK-9999-01C
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05557045 2026-03-12
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
Jazz Pharmaceuticals
Phase 1 Recruiting
NCT05968326 2026-03-12
IMCODE003
Genentech, Inc.
Phase 2 Recruiting
NCT06445140 2026-03-12
MONAGE
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Recruiting
NCT06959810 2026-03-12
OEUVRE
Centre Francois Baclesse
Phase NA Recruiting
NCT06901531 2026-03-11
LUCERNA
Astellas Pharma Inc
Phase 3 Recruiting
NCT04333706 2026-03-10
EMPOWER
University of Southern California
Phase 1/2 Recruiting
NCT03366116 2026-03-09
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT04449549 2026-03-09
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT04723810 2026-03-09
TumorGlow Intraoperative Molecular Imaging (IMI)
University of Pennsylvania
Phase 1/2 Recruiting
NCT07454330 2026-03-09
Study of a Support Program for Quality of Life in Chinese Cancer Patients and Survivors
Memorial Sloan Kettering Cancer Center
Phase NA Recruiting
NCT05831579 2026-03-06
Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy
Washington University School of Medicine
Phase NA Recruiting
NCT05886764 2026-03-06
Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials
University of Chicago
Phase NA Recruiting
NCT06311214 2026-03-06
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06555744 2026-03-06
A Study of ZW191 in Participants With Solid Tumors
Zymeworks BC Inc.
Phase 1 Recruiting
NCT06564233 2026-03-06
Supportive Care Intervention for Outpatient Stem Cell Transplant Patients
Friendi.fi Corporation
Phase NA Recruiting
NCT06905002 2026-03-06
Enhancing the Patient Journey to Clinical Trial Enrolment With Navigation to Optimize Accrual
Windsor Regional Hospital
Phase NA Recruiting
NCT06979596 2026-03-06
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT04713046 2026-03-05
Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Recruiting
NCT06807593 2026-03-05
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03435796 2026-03-04
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Celgene
Phase 2/3 Recruiting
NCT05004116 2026-03-04
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT05508464 2026-03-04
ARREST2
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase NA Recruiting
NCT06409065 2026-03-04
Psycho-Spiritual Management for Patients With Advanced Cancer and Their Family Caregivers
M.D. Anderson Cancer Center
Phase NA Recruiting
NCT06713369 2026-03-04
AZD5305
AstraZeneca
Phase 1 Recruiting
NCT06803680 2026-03-04
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT03391778 2026-03-03
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
USWM, LLC (dba US WorldMeds)
Phase 1 Recruiting
NCT07046559 2026-03-03
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants
Eli Lilly and Company
Phase 1 Recruiting
NCT05382559 2026-03-02
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting